Give me in vivo and in vitro models for anticancer activity with article link
Searching PubMed
in vitro in vivo models anticancer activity screening
Searching the Web
in vivo and in vitro models for anticancer activity research review 2023 2024
Reading Article
Searching PubMed
preclinical cancer models cell lines xenograft organoids review
Reading Web Page
in vitro in vivo models anticancer activity
Here is a comprehensive, well-referenced breakdown of in vitro and in vivo models used for anticancer activity evaluation:
IN VITRO Models for Anticancer Activity
1. 2D Cell Culture (Monolayer Culture)
The most widely used starting point. Cancer cell lines are grown as flat monolayers on culture plates.
Common cancer cell lines:
| Cell Line | Cancer Type |
|---|---|
| MCF-7, MDA-MB-231 | Breast cancer |
| HeLa | Cervical cancer |
| A549, H460 | Non-small cell lung cancer |
| HCT116, SW480 | Colorectal cancer |
| PC-3, LNCaP | Prostate cancer |
| HepG2 | Hepatocellular carcinoma |
| U87, U251 | Glioblastoma |
| HL-60, K562 | Leukemia |
Key assays performed:
- MTT/MTS/WST-1 assay - cell viability and IC50 determination
- SRB (Sulforhodamine B) assay - NCI standard cytotoxicity screen
- Clonogenic (colony formation) assay - long-term proliferative capacity
- BrdU/Ki-67 proliferation assay
- Flow cytometry - cell cycle analysis, apoptosis (Annexin V/PI)
- Caspase-3/7 activation assay - apoptosis pathway
- Wound scratch assay - cell migration
- Transwell invasion assay - invasion/metastasis potential
- Western blot / qRT-PCR - molecular pathway analysis
2. 3D Spheroid Models
Three-dimensional tumor spheroids better mimic tumor architecture, hypoxic cores, and drug penetration barriers.
- Multicellular tumor spheroids (MCTS) - self-assembled spheroids from cancer cell lines
- Scaffold-based 3D cultures - Matrigel, collagen matrices
- Hanging drop method, ultra-low attachment plates
Advantages: Recapitulate oxygen/nutrient gradients, drug resistance more accurately than 2D; better predict in vivo outcomes.
3. Organoids (Patient-Derived Organoids - PDOs)
Miniaturized 3D organ-like structures derived from patient tumor tissue embedded in basement membrane matrix.
- Preserve tumor heterogeneity and genetic architecture
- Used for drug sensitivity testing personalized to each patient
- Available for lung, colon, pancreatic, prostate, breast cancers
4. Co-culture Models
Cancer cells co-cultured with stromal cells (fibroblasts, endothelial cells, immune cells) to simulate the tumor microenvironment (TME).
5. Organ-on-a-Chip / Microfluidic Models
Microfluidic devices that simulate vascular flow, drug delivery, and tumor-stroma interactions. Emerging platform for pharmacokinetic-pharmacodynamic modeling.
IN VIVO Models for Anticancer Activity
1. Xenograft Models (Subcutaneous/Ectopic)
Human tumor cell lines injected subcutaneously into immunodeficient mice (nude, SCID, NSG).
- Most common: flank xenograft
- Easy to measure tumor volume with calipers
- Endpoints: tumor volume, weight, survival
2. Orthotopic Models
Tumor cells implanted into the organ of origin (e.g., breast cancer cells in mammary fat pad, lung cancer cells intratracheally).
- Better recapitulates tumor biology and metastatic behavior
3. Patient-Derived Xenograft (PDX) Models
Fresh patient tumor tissue (not cell lines) is implanted into immunodeficient mice.
- Preserves patient tumor heterogeneity, stroma, architecture
- Best predictor of clinical drug response among animal models
- Used in co-clinical trials
4. Syngeneic Models
Murine tumor cell lines injected into immunocompetent mice of the same genetic background (e.g., 4T1 in BALB/c, B16-F10 in C57BL/6).
- Fully functional immune system - essential for immunotherapy testing
- Common lines: 4T1 (breast), CT26 (colon), B16-F10 (melanoma), LLC (lung)
5. Genetically Engineered Mouse Models (GEMMs)
Mice engineered to carry cancer-driving mutations (oncogenes or tumor suppressor knockouts).
- Tumors arise spontaneously - most physiologically relevant
- Examples: MMTV-PyMT (breast), KrasG12D/Trp53fl/fl (pancreatic, lung)
- Useful for studying tumorigenesis, prevention, early-stage therapy
6. Hollow Fiber Assay (NCI Model)
Tumor cells grown inside hollow fibers implanted intraperitoneally or subcutaneously in mice. NCI used this as a rapid in vivo screen.
7. Zebrafish (Danio rerio) Models
- Transparent embryos allow real-time visualization of tumor growth and angiogenesis
- Xenograft models in zebrafish: human cancer cells injected into larvae
- High-throughput, cost-effective, shorter timelines than rodent models
8. Metastasis Models
- Tail vein injection - experimental lung metastasis
- Intracardiac injection - multi-organ metastasis
- Portal vein injection - liver metastasis
Key References with Links
| # | Article | Link |
|---|---|---|
| 1 | Abreu et al. (2021) - "In Vitro and In Vivo Tumor Models for the Evaluation of Anticancer Nanoparticles" - Adv Exp Med Biol - PMID 33543464 | PubMed |
| 2 | Stribbling et al. (2024) - "Orthotopic and metastatic tumour models in preclinical cancer research" - Pharmacol Ther - PMID 38467308 | PubMed |
| 3 | Sailer et al. (2023) - "Experimental in vitro, ex vivo and in vivo models in prostate cancer research" - Nat Rev Urol - PMID 36451039 | PubMed |
| 4 | Salu & Reindl (2024) - "Advancements in Preclinical Models of Pancreatic Cancer" - Pancreas - PMID 38206758 | PubMed |
| 5 | Frontiers (2026) - "Preclinical screening models in anticancer drug development: strengths, limitations, and translational challenges" - Front Pharmacol | Full Article |
| 6 | PMC Review - "In Vitro and In Vivo Models for Analysis of Resistance to Anticancer Molecular Therapies" | PMC Full Text |
| 7 | MDPI Cancers (2021) - "Pre-Clinical In Vitro Models Used in Cancer Research: Results of a Worldwide Survey" | Full Article |
| 8 | Technology Networks (2024) - "In Vitro Models Revolutionizing Cancer Drug Discovery" | Article |
Summary Comparison
| Feature | 2D In Vitro | 3D/Organoids | Xenograft | PDX | GEMM | Syngeneic |
|---|---|---|---|---|---|---|
| Cost | Low | Moderate | Moderate | High | Very High | Moderate |
| Throughput | High | Moderate | Low | Low | Very Low | Low |
| Tumor microenvironment | No | Partial | Partial | Yes | Yes | Yes |
| Immune system | No | No | No | No | Yes | Yes |
| Human relevance | Moderate | High | Moderate | High | Low | Low |
| Regulatory acceptance | Initial screen | Supplementary | Required | Supplementary | Required | Required |
The standard workflow for anticancer drug development is: 2D cell lines → 3D spheroids/organoids → xenograft or syngeneic in vivo → PDX validation → clinical trials, as described in the 2026 Frontiers Pharmacology review. Only about 5% of preclinical candidates make it to clinical implementation, underscoring the importance of choosing the right model at each stage.
This is a shared conversation. Sign in to Orris to start your own chat.